Trial · NCT05432414
PVd Versus Vd in NDMM Patients With RI
NCT05432414, Phase 2, Unknown, RenJi Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PVd Versus Vd in NDMM Patients With RI. Trials, record NCT05432414. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05432414
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PVd Versus Vd in NDMM Patients With RI
- NCT number
- NCT05432414
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 79 participants, estimated
- Lead sponsor
- RenJi Hospital
- Conditions
- Multiple Myeloma
- Interventions
- pomalidomide, Bortezomib, Dexamethasone
- First posted
- 2022-06-27
- Last updated
- 2023-01-31
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ≥very good partial response | At end of cycle 4 (each cycle is 21 days) | The sum of a complete response and a very good partial response |
| Secondary | MRD negative rate | From randomization to the date of first documented evidence of PD until study completion, an average of 1.5 year | When patients reached CR, NGF was used to detect the proportion of patients with bone marrow clonoplasma cells without phenotypic abnormalities. The minimum detection sensitivity was 1 clonoplasma cell in 10000 nucleated cells |
| Secondary | immunologic function | At day 1±3 of cycle 2-5 (each cycle is 21 days) | Twelve cytokine assays, lymphocyte subsets and absolute count, Treg cell assays, lymphocyte activation marker assays, TH1/TH2/TH17 subsets of cytokines assays |
| Secondary | renal tubular function | At day 1±3 of cycle 2-5 (each cycle is 21 days) | Renal remission rate was evaluated according to the 2016 IMWG expert consensus on MM renal injury |
| Secondary | safety（Number of adverse events ） | Each cycle (each cycle is 21 days), up to 24 months of follow-up | Number of adverse events according to symptoms, physical examination and scheduled laboratory tests |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42716009 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05432414
GET https://conductscience.org/api/trials/v1/NCT05432414/registered